GlassScriptPhysician profile
Margaret D Kellar
NPI 1124644802
$6,529.69
in general payments reported to CMS, 2019-2025
22 companies · $1,667 in 2025
The $1,667 reported for 2025 was more than what 90% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $806 · 2022: $1,379 · 2023: $1,378 · 2024: $1,299 · 2025: $1,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,344.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,913.83 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,059.50 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $506.84 | 2021-2025 | Ingrezza |
| Lundbeck LLC | $498.79 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $356.63 | 2021-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $340.05 | 2023-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $322.14 | 2021-2025 | Azstarys |
| Alkermes, INC. | $290.53 | 2021-2024 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $268.68 | 2022-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $181.37 | 2022-2025 | Spravato |
| Vanda Pharmaceuticals INC. | $180.05 | 2021-2025 | Fanapt |
| Bausch Health US, LLC | $177.34 | 2021-2024 | Wellbutrin, Aplenzin |
| Teva Pharmaceuticals USA, INC. | $173.37 | 2022-2025 | Uzedy, Austedo, Austedo Xr |
| Supernus Pharmaceuticals, INC. | $87.12 | 2021-2025 | Qelbree |
| Eisai INC. | $37.43 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.98 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $23.10 | 2023 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $19.26 | 2022 | |
| Allergan, INC. | $18.34 | 2021 | |
| Indivior INC. | $14.22 | 2023 | Perseris |
| Neos Therapeutics, LP | $14.13 | 2023 | Adzenys Xr-Odt |
| Sunovion Pharmaceuticals INC. | $11.99 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Kellar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.